Adni vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Singapore YC healthcare worker super app with 150K+ verified nurses for peer advice, jobs, and credential management at $1.8M ARR Jul 2025; $1.38M Flare Capital seed with Penn Medicine/MedPro partnerships competing with Doximity for allied health professionals.
About
Adni is a Singapore-headquartered AI-powered super app for healthcare workers — backed by Y Combinator with $1.38 million raised including a $1.25 million seed round in May 2022 from YC, Flare Capital Partners, and Fresco Capital — providing 150,000+ verified nurses and allied healthcare professionals with a unified platform for anonymous peer advice sharing, job discovery, credential management (universal professional profile storing licenses, certifications, and continuing education records), equipment procurement, and community resources, generating $1.8 million in annual revenue as of July 2025 with approximately 32 employees across Asia and North America. Adni partners with leading healthcare organizations including Penn Medicine, MedPro, and PRN Healthcare to provide nurses and allied health workers with the professional tools that their clinical training institutions and hospital employers don't provide.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.